- Home
- WBX vs PRQR Comparison
WBX vs PRQR Comparison
Compare WBX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- PRQR
- Stock Information
- Founded
- WBX 2015
- PRQR 2012
- Country
- WBX Spain
- PRQR Netherlands
- Employees
- WBX N/A
- PRQR N/A
- Industry
- WBX Industrial Specialties
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- PRQR Health Care
- Exchange
- WBX Nasdaq
- PRQR Nasdaq
- Market Cap
- WBX 293.9M
- PRQR 309.5M
- IPO Year
- WBX N/A
- PRQR 2014
- Fundamental
- Price
- WBX $0.44
- PRQR $2.69
- Analyst Decision
- WBX Buy
- PRQR Strong Buy
- Analyst Count
- WBX 3
- PRQR 5
- Target Price
- WBX $1.42
- PRQR $7.60
- AVG Volume (30 Days)
- WBX 648.0K
- PRQR 605.4K
- Earning Date
- WBX 11-06-2024
- PRQR 11-07-2024
- Dividend Yield
- WBX N/A
- PRQR N/A
- EPS Growth
- WBX N/A
- PRQR N/A
- EPS
- WBX N/A
- PRQR N/A
- Revenue
- WBX $179,622,844.00
- PRQR $20,506,357.00
- Revenue This Year
- WBX $20.24
- PRQR $235.11
- Revenue Next Year
- WBX $16.77
- PRQR N/A
- P/E Ratio
- WBX N/A
- PRQR N/A
- Revenue Growth
- WBX 16.10
- PRQR 306.68
- 52 Week Low
- WBX $0.45
- PRQR $1.61
- 52 Week High
- WBX $1.98
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- WBX 29.88
- PRQR 37.43
- Support Level
- WBX $0.45
- PRQR $2.48
- Resistance Level
- WBX $0.58
- PRQR $2.83
- Average True Range (ATR)
- WBX 0.06
- PRQR 0.28
- MACD
- WBX -0.00
- PRQR -0.06
- Stochastic Oscillator
- WBX 3.10
- PRQR 26.01
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates smart charging system combining technology design that manages the communication between user, vehicle, grid, building, and charger. The company is engaged in designing, manufacturing, and distributing faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA) which is also its key revenue generating segment, North America, and Asia‑Pacific.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.